Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1126-1135

  Berkers, Celia R ^a   Leestemaker, Yves ^a   Schuurman, Karianne G ^a   Ruggeri, Bruce ^b   Jones Bolin, Susan ^b   Williams, Michael ^b   Ovaa, Huib ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CEPHALON INC   (United States)

Author keywords

activity profiling; bortezomib; delanzomib; proteasome; proteasome inhibitor

Indexed keywords

BORTEZOMIB; DELANZOMIB; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MICE; MICE, SCID; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84860768745     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp2004143     Document Type: Article

References (34)

1. Adams, J. The development of proteasome inhibitors as anticancer drugs Cancer Cell 2004, 5 (5) 417-421
2. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system Nat. Rev. Drug Discovery 2006, 5 (7) 596-613
3. Dahlmann, B.; Ruppert, T.; Kuehn, L.; Merforth, S.; Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties J. Mol. Biol. 2000, 303 (5) 643-653
4. Dahlmann, B.; Ruppert, T.; Kloetzel, P. M.; Kuehn, L. Subtypes of 20S proteasomes from skeletal muscle Biochimie 2001, 83 (3-4) 295-299
5. Pelletier, S.; Schuurman, K. G.; Berkers, C. R.; Ovaa, H.; Heck, A. J.; Raijmakers, R. Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry Mol. Biosyst. 2010, 6 (8) 1450-1453
6. Raijmakers, R.; Berkers, C. R.; de Jong, A.; Ovaa, H.; Heck, A. J.; Mohammed, S. Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity Mol. Cell. Proteomics 2008, 7 (9) 1755-1762
7. Adams, J. The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 2004, 4 (5) 349-360
8. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res. 2001, 61 (7) 3071-3076
9. Jagannath, S.; Barlogie, B.; Berenson, J.; Siegel, D.; Irwin, D.; Richardson, P. G.; Niesvizky, R.; Alexanian, R.; Limentani, S. A.; Alsina, M.; Adams, J.; Kauffman, M.; Esseltine, D. L.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br. J. Haematol. 2004, 127 (2) 165-172
10. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 2003, 348 (26) 2609-2617
11. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 2005, 352 (24) 2487-2498
12. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J. Clin. Oncol. 2006, 24 (30) 4867-4874
13. Orlowski, R. Z.; Nagler, A.; Sonneveld, P.; Blade, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N.; Spicka, I.; Sutherland, H. J.; Suvorov, A. N.; Zhuang, S. H.; Parekh, T.; Xiu, L.; Yuan, Z.; Rackoff, W.; Harousseau, J. L. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J. Clin. Oncol. 2007, 25 (25) 3892-3901
14. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade Clin. Cancer Res. 2008, 14 (6) 1649-1657
15. Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennett, M. K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 2007, 67 (13) 6383-6391
16. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen, F. W.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 2007, 110 (9) 3281-3290
17. Stapnes, C.; Doskeland, A. P.; Hatfield, K.; Ersvaer, E.; Ryningen, A.; Lorens, J. B.; Gjertsen, B. T.; Bruserud, O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells Br. J. Haematol. 2007, 136 (6) 814-828
18. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T. H.; Neuteboom, S. T.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 2005, 8 (5) 407-419
19. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052) Bioorg. Med. Chem. 2009, 17 (6) 2175-2180
20. Dorsey, B. D.; Iqbal, M.; Chatterjee, S.; Menta, E.; Bernardini, R.; Bernareggi, A.; Cassara, P. G.; D'Arasmo, G.; Ferretti, E.; De Munari, S.; Oliva, A.; Pezzoni, G.; Allievi, C.; Strepponi, I.; Ruggeri, B.; Ator, M. A.; Williams, M.; Mallamo, J. P. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer J. Med. Chem. 2008, 51 (4) 1068-1072
21. Piva, R.; Ruggeri, B.; Williams, M.; Costa, G.; Tamagno, I.; Ferrero, D.; Giai, V.; Coscia, M.; Peola, S.; Massaia, M.; Pezzoni, G.; Allievi, C.; Pescalli, N.; Cassin, M.; di Giovine, S.; Nicoli, P.; de Feudis, P.; Strepponi, I.; Roato, I.; Ferracini, R.; Bussolati, B.; Camussi, G.; Jones-Bolin, S.; Hunter, K.; Zhao, H.; Neri, A.; Palumbo, A.; Berkers, C.; Ovaa, H.; Bernareggi, A.; Inghirami, G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood 2008, 111 (5) 2765-2775
22. Lightcap, E. S.; McCormack, T. A.; Pien, C. S.; Chau, V.; Adams, J.; Elliott, P. J. Proteasome inhibition measurements: clinical application Clin. Chem. 2000, 46 (5) 673-683
23. Berkers, C. R.; Verdoes, M.; Lichtman, E.; Fiebiger, E.; Kessler, B. M.; Anderson, K. C.; Ploegh, H. L.; Ovaa, H.; Galardy, P. J. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib Nat. Methods 2005, 2 (5) 357-362
24. Berkers, C. R.; van Leeuwen, F. W.; Groothuis, T. A.; Peperzak, V.; van Tilburg, E. W.; Borst, J.; Neefjes, J. J.; Ovaa, H. Profiling proteasome activity in tissue with fluorescent probes Mol. Pharmaceutics 2007, 4 (5) 739-748
25. Lamanda, A.; Zahn, A.; Roder, D.; Langen, H. Improved Ruthenium II tris (bathophenantroline disulfonate) staining and destaining protocol for a better signal-to-background ratio and improved baseline resolution Proteomics 2004, 4 (3) 599-608
26. Rabilloud, T.; Strub, J. M.; Luche, S.; van Dorsselaer, A.; Lunardi, J. A comparison between Sypro Ruby and ruthenium II tris (bathophenanthroline disulfonate) as fluorescent stains for protein detection in gels Proteomics 2001, 1 (5) 699-704
27. Altun, M.; Galardy, P. J.; Shringarpure, R.; Hideshima, T.; LeBlanc, R.; Anderson, K. C.; Ploegh, H. L.; Kessler, B. M. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells Cancer Res. 2005, 65 (17) 7896-7901
28. Oerlemans, R.; Franke, N. E.; Assaraf, Y. G.; Cloos, J.; van Zantwijk, I.; Berkers, C. R.; Scheffer, G. L.; Debipersad, K.; Vojtekova, K.; Lemos, C.; van der Heijden, J. W.; Ylstra, B.; Peters, G. J.; Kaspers, G. L.; Dijkmans, B. A.; Scheper, R. J.; Jansen, G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 2008, 112 (6) 2489-2499
29. Lu, S.; Yang, J.; Song, X.; Gong, S.; Zhou, H.; Guo, L.; Song, N.; Bao, X.; Chen, P.; Wang, J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line J. Pharmacol. Exp. Ther. 2008, 326 (2) 423-431
30. Ri, M.; Iida, S.; Nakashima, T.; Miyazaki, H.; Mori, F.; Ito, A.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; Shiotsu, Y.; Ueda, R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress Leukemia 2010, 24 (8) 1506-1512
31. Lonial, S.; Waller, E. K.; Richardson, P. G.; Jagannath, S.; Orlowski, R. Z.; Giver, C. R.; Jaye, D. L.; Francis, D.; Giusti, S.; Torre, C.; Barlogie, B.; Berenson, J. R.; Singhal, S.; Schenkein, D. P.; Esseltine, D. L.; Anderson, J.; Xiao, H.; Heffner, L. T.; Anderson, K. C. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma Blood 2005, 106 (12) 3777-3784
32. Argyriou, A. A.; Iconomou, G.; Kalofonos, H. P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood 2008, 112 (5) 1593-1599
33. Kisselev, A. F.; Callard, A.; Goldberg, A. L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate J. Biol. Chem. 2006, 281 (13) 8582-8590
34. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 2006, 14 (3) 451-456